

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-105) CRIZANLIZUMAB
 PRONUNCIATION kriz" an liz' ue mab
 THERAPEUTIC CLAIM Treatment of sickle-cell disease

CHEMICAL NAMES

1. Immunoglobulin G2, anti-(human P-selectin) (human-*Mus musculus* monoclonal SelG1 heavy chain), disulfide with human-*Mus musculus* monoclonal SelG1 light chain, dimer
2. Immunoglobulin G2-kappa, anti-(*Homo sapiens* P-selectin glycoprotein ligand (CD62 antigen)); humanized monoclonal antibody; γ 2 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-8*01 (82%) –(IGHD)-IGHJ4*01 [8.8.15] (1-122) -*Homo sapiens* IGHG2*02 {CH2[K¹⁰⁵>A(323)]} (123-448)) (136-218')-disulfide with κ light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87%) –IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')], dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGASVKV	SCKVSGYTFT	SYDINWVRQA	PGKGLEWMGW	50
IYPGDGSIKY	NEKFKGRVTM	TVDKSTDTAY	MELSSLRSED	TAVYYCARRG	100
EYGNIEGAMD	YWGQGTLLTV	SSASTKGPSV	FPLAPCSRST	SESTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVTSSNFGT	200
QTYTCNVVHK	PSNTKVDKTV	ERKCCVECPP	CPAPPVAGPS	VFLFPPKPKD	250
TLMISRTPPEV	TCVVVDVSH	DPEVQFNWYV	DGMEVHNAKT	KPREEQFNST	300
FRVVSVLTIV	HQDWLNGKEY	KCAVSNKGLP	APIEKTISK	KGQPREPQVY	350
TLPPSREEMT	KNQVSLTCLV	KGFYPSDIAV	EWESNGQPEN	NYKTPPMLD	400
SDGSFFLYSK	LTVDKSRWQQ	GNVFSCSVMH	EALHNHYTQK	SLSLSPGK	448

Light chain

DIQMTQSPSS	LSASVGRVT	ITCKASQSV	YDGHSYMNWY	QQKPGKAPKL	50'
LIYAASNLES	GVPSRFSGSG	SGTDFTLTIS	SLQPEDFATY	YCQQSDENPL	100'
TFGGGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCCL	NNFYPREAKV	150'
QWKVDNALQS	GNSQESVTEQ	DSKSTYSLS	STLTLSKADY	EKHKVYACEV	200'
THQGLSSPVT	KSFNRGEC				218'

Disulfide bridges

22-96	22"-96"	23'-92'	23'''-92'''	136-218"	136"-218'''
138'-198"	138'''-198'''	149-205	149"-205"	224-224"	225-225"
228-228"	231-231"	262-322	262"-322"	368-426	368"-426"

Glycosylation sites (N)

Asn-298 Asn-298"

MOLECULAR FORMULA C₆₄₅₈H₉₉₄₈N₁₇₁₂O₂₀₅₀S₅₈

MOLECULAR WEIGHT 146.23 kDa (non-glycosylated)

TRADEMARK None as yet

SPONSOR	Novartis Pharma AG
CODE DESIGNATIONS	SEG101, SeIG1, NVP-LXI262
<u>CAS</u> REGISTRY NUMBER	1690318-25-2
UNII	L7451S9126
WHO NUMBER	10316

gbk